ServiceNow (NOW) rated new outperform at JMP Securities. $56 price target. Company is a cloud leader in IT Service Management.
Pharmacyclics (PCYC) upgraded at Lazard to buy, Lazard Capital Markets said. $141 price target. Checks show a strong outlook for ibrutinib.
Rowan (RDC) upgraded at JP Morgan from neutral to overweight, JP Morgan said. Dayrates have likely bottomed. $39 price target.
Select Medical (SEM) downgraded at Wells from market perform to underperform, Wells Fargo said. Long-term acute care hospitals will face Medicare reimbursement risks in 2015.Vivus (VVUS) downgraded at Lazard to sell, Lazard Capital Markets said. $8 price target. Qsymia has had a slow launch and the company's patents could face competition. Verizon (VZ - Get Report) upgraded at Baird from neutral to outperform, Robert Baird said. $53 price target. VZW purchase should benefit long-term positioning and earnings growth.